SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-005744
Filing Date
2020-05-07
Accepted
2020-05-07 16:31:28
Documents
79
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20200331x10q.htm 10-Q 1276134
2 EX-10.5 acrs-20200331ex105bdce95.htm EX-10.5 16087
3 EX-31.1 acrs-20200331ex311f07fff.htm EX-31.1 14886
4 EX-31.2 acrs-20200331ex3129e6165.htm EX-31.2 14892
5 EX-32.1 acrs-20200331ex3213de2b1.htm EX-32.1 9010
  Complete submission text file 0001558370-20-005744.txt   7529065

Data Files

Seq Description Document Type Size
6 EX-101.INS acrs-20200331.xml EX-101.INS 1973157
7 EX-101.SCH acrs-20200331.xsd EX-101.SCH 51981
8 EX-101.CAL acrs-20200331_cal.xml EX-101.CAL 59944
9 EX-101.DEF acrs-20200331_def.xml EX-101.DEF 181852
10 EX-101.LAB acrs-20200331_lab.xml EX-101.LAB 529684
11 EX-101.PRE acrs-20200331_pre.xml EX-101.PRE 363738
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 20856972
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences